Orexigen Obesity Drug Produces “Modest” Weight Loss, Lowers Cardiovascular Risk |  |
|
Posted by Mary Canady June 6th, 2009 .
| |
| No Comments |
Orexigen Therapeutics, the San Diego-based obesity drug developer, underwhelmed investors back in January with its incremental ability to help patients lose weight. But now the company is presenting...
[[Click headline to continue reading.]]
[[Click headline to continue reading.]]
See other entries categorized in News, Syndication, Xconomy.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
